Company registration number 14605109 (England and Wales)
CLEARVIEW MEDTECH LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025
PAGES FOR FILING WITH REGISTRAR
Affinia
19th Floor
1 Westfield Avenue
London
E20 1HZ
CLEARVIEW MEDTECH LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 8
CLEARVIEW MEDTECH LIMITED
BALANCE SHEET
AS AT 31 OCTOBER 2025
31 October 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Investments
5
8,604,664
8,599,072
Current assets
Debtors
6
9,442
Cash at bank and in hand
2,035
500
2,035
9,942
Creditors: amounts falling due within one year
7
(3,455,282)
(2,143,987)
Net current liabilities
(3,453,247)
(2,134,045)
Total assets less current liabilities
5,151,417
6,465,027
Creditors: amounts falling due after more than one year
8
(7,175,000)
(7,325,000)
Provisions for liabilities
(250,000)
(494,408)
Net liabilities
(2,273,583)
(1,354,381)
Capital and reserves
Called up share capital
9
12
12
Share premium account
62,488
62,488
Profit and loss reserves
(2,336,083)
(1,416,881)
Total equity
(2,273,583)
(1,354,381)
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true
The financial statements were approved by the board of directors and authorised for issue on 30 April 2026 and are signed on its behalf by:
Mrs A Price
Director
Company registration number 14605109 (England and Wales)
CLEARVIEW MEDTECH LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025
- 2 -
1
Accounting policies
Company information
Clearview Medtech Limited is a private company limited by shares incorporated in England and Wales. The registered office is 1-4 Walls Yard, Riverside Industrial Estate, South Street, Rochford, Essex, SS4 1GR.
1.1
Basis of preparation
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.
1.2
Going concern
Atruet the time of approving the financial statements, the company had net liabilities. However, group support has been committed to ensure that the company is able to meet its obligations as they fall due for at lease 12 months following the date of approval. The directors have considered a period of 12 months from the date of singing the financial statements and in conclusion have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.
1.3
Fixed asset investments
Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.
A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.
An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a long-term interest and where the company has significant influence. The company considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.
Entities in which the company has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities.
1.4
Cash and cash equivalents
Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.
CLEARVIEW MEDTECH LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
1
Accounting policies
(Continued)
- 3 -
1.5
Financial instruments
The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.
Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.
Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
Basic financial liabilities
Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
1.6
Equity instruments
Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.
1.7
Taxation
The tax expense represents the sum of the tax currently payable and deferred tax.
Current tax
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
CLEARVIEW MEDTECH LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
1
Accounting policies
(Continued)
- 4 -
Deferred tax
Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.
1.8
Provisions
Provisions are recognised when the company has a legal or constructive present obligation as a result of a past event, it is probable that the company will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.
The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the reporting end date, taking into account the risks and uncertainties surrounding the obligation. Where the effect of the time value of money is material, the amount expected to be required to settle the obligation is recognised at present value. When a provision is measured at present value, the unwinding of the discount is recognised as a finance cost in profit or loss in the period in which it arises.
1.9
Retirement benefits
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.
2
Judgements and key sources of estimation uncertainty
In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.
3
Employees
The average monthly number of persons (including directors) employed by the company during the year was:
2025
2024
Number
Number
Total
4
4
CLEARVIEW MEDTECH LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
- 5 -
4
Interest payable and similar expenses
2025
2024
£
£
Interest payable and similar expenses includes the following:
Interest on bank overdrafts and loans
104,151
127,587
Other interest on financial liabilities
775,514
822,090
879,665
949,677
5
Fixed asset investments
2025
2024
£
£
Shares in group undertakings and participating interests
8,604,664
8,599,072
Movements in fixed asset investments
Shares in subsidiaries
£
Cost or valuation
At 1 November 2024
8,599,072
Additions
5,592
At 31 October 2025
8,604,664
Carrying amount
At 31 October 2025
8,604,664
At 31 October 2024
8,599,072
6
Debtors
2025
2024
Amounts falling due within one year:
£
£
Other debtors
9,442
7
Creditors: amounts falling due within one year
2025
2024
£
£
Bank loans
150,000
150,000
Other creditors
3,305,282
1,993,987
3,455,282
2,143,987
CLEARVIEW MEDTECH LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
- 6 -
8
Creditors: amounts falling due after more than one year
2025
2024
£
£
Bank loans and overdrafts
6,927,500
7,077,500
Other creditors
247,500
247,500
7,175,000
7,325,000
The company has a fixed and floating charge containing negative pledge over all the assets, property and undertaking of the company, in favour of Foresight Fund Mangers Limited dated 25th May 2023.
The company has a fixed and floating charge containing negative pledge over all the assets, property and undertaking of the company, in favour of Clydesdale Bank PLC dated 25th May 2023.
9
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
A Ordinary of 0.1p each
8,889
8,889
9
9
B Ordinary of 0.1p each
370
370
C Ordinary of 0.1p each
741
741
1
1
D Ordinary of 0.1p each
2,070
2,070
2
2
12,070
12,070
12
12
Ordinary A, B and C shares carry equal voting rights. Ordinary D shares do not carry any voting rights.
Ordinary A, B and C shares rank equally for dividends. The maximum amount that Ordinary D shares as a class are entitled to receive are 18.8% of any such distribution.
10
Audit report information
As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006.
The auditor's report is unqualified.
Senior Statutory Auditor:
Mark Middleton
Statutory Auditor:
Affinia (Stratford)
Date of audit report:
30 April 2026
CLEARVIEW MEDTECH LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
- 7 -
11
Related party transactions
Transactions with related parties
During the year the company entered into the following transactions with related parties:
Management charges
2025
2024
£
£
Entities with control, joint control or significant influence over the company
57,786
55,964
2025
2024
Amounts due to related parties
£
£
Entities with control, joint control or significant influence over the company
6,810,899
7,058,996
Included in amounts due to entities which have control over the company is a balance of £5,940,000 which attracts interest at a rate of 8% per annum above the Bank of England base rate.
Included in amounts due to other related parties is a balance of £247,500 which attracts interest at a rate of 8% per annum above the Bank of England base rate.
Other information
Parties included within 'other related parties' are related due to being shareholding directors of the business.
Intercompany recharges are based on a standardised proportion of costs incurred being recharged to the other related party, due to this entity's head office activities.
All balances with other related parties are unsecured, and no guarantees have been given or received by any such party.
There are no provisions for uncollectible receivables related to the amount of outstanding balances, and no expense has been recognised during the period in respect of bad or doubtful debts due from related parties.
All liabilities are to be settled via a transfer of funds to the related parties.
12
Directors' transactions
Dividends totalling £0 (2024 - £0) were paid in the year in respect of shares held by the company's directors.
At the balance sheet date the company owed £283,286 (2024: £294,518) to the directors.
Included in amounts due to Directors is a balance of £247,500 which attracts interest at a rate of 8% per annum above the Bank of England base rate.
CLEARVIEW MEDTECH LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
- 8 -
13
Parent company
The immediate parent company is Foresight Regional Investment II LLP, a partnership incorporated in England & Wales (Partnership number: LP020316).
The Ultimate controlling party is Foresight Group Holdings Limited a company registered in Guernsey. (Company number: FC038787).